Literature DB >> 27141394

Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course.

An Coosemans1, Judit Decoene2, Thaïs Baert1, Annouschka Laenen3, Ahmad Kasran4, Tina Verschuere5, Sven Seys4, Ignace Vergote1.   

Abstract

Neoplastic cells can escape immune control leading to cancer growth. Regulatory T cells (Treg), myeloid-derived suppressor cells (MDSC) and tumor-associated macrophages (TAM) are crucial in immune escape. TAM are divided based on their immune profile, M1 are immunostimulatory while M2 are immunosuppressive. Research so far has mainly focused on the intratumoral behavior of these cells. This study, on the other hand, explored the systemic changes of the key metabolites [IL-4 (interleukin), IL-13, arginase, IL-10, VEGF-A (vascular endothelial growth factor), CCL-2 (chemokine (C-C) motif ligand 2) and TGF-β (transforming growth factor)] linked to Treg, MDSC and TAM during the course of the disease in ovarian and fallopian tube cancer patients. Serum samples were therefore analyzed at diagnosis, after (interval)-debulking surgery and after chemotherapy (paclitaxel-carboplatin). We also determined galectin-1 (gal-1), involved in angiogenesis and tumor-mediated immune evasion. We found significantly lower levels of IL-10, VEGF-A, TGF-β and arginase and higher levels of gal-1 after chemotherapy compared to diagnosis. After debulking surgery, a decrease in IL-10 was significant. Gal-1 and CCL-2 appeared independent prognostic factors for progression-free and overall survival (OS) (multivariate analysis). These results will help us in the decision making of future therapies in order to further modulate the immune system in a positive way.

Entities:  

Keywords:  Arginase; CCL-2; VEGF; debulking; galectin-1; immunosuppression; ovarian cancer; paclitaxel–carboplatin

Year:  2015        PMID: 27141394      PMCID: PMC4839325          DOI: 10.1080/2162402X.2015.1111505

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  55 in total

Review 1.  VEGF and tumour angiogenesis. Impact of surgery, wound healing, inflammation and blood transfusion.

Authors:  Mads Nordahl Svendsen; Kim Werther; Hans Jørgen Nielsen; Paul E G Kristjansen
Journal:  Scand J Gastroenterol       Date:  2002-04       Impact factor: 2.423

2.  CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes.

Authors:  Amanda Nickles Fader; Nabila Rasool; Susan A J Vaziri; Toshiyuki Kozuki; Pieter W Faber; Paul Elson; Charles V Biscotti; Chad M Michener; Peter G Rose; Luis Rojas-Espaillat; Jerome L Belinson; Mahrukh K Ganapathi; Ram Ganapathi
Journal:  Anticancer Res       Date:  2010-12       Impact factor: 2.480

3.  Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity.

Authors:  Andrea Casazza; Damya Laoui; Mathias Wenes; Sabrina Rizzolio; Nicklas Bassani; Marco Mambretti; Sofie Deschoemaeker; Jo A Van Ginderachter; Luca Tamagnone; Massimiliano Mazzone
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

Review 4.  Myeloid-derived suppressor cells in human cancer.

Authors:  Srinivas Nagaraj; Dmitry I Gabrilovich
Journal:  Cancer J       Date:  2010 Jul-Aug       Impact factor: 3.360

5.  Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors.

Authors:  Diego O Croci; Juan P Cerliani; Tomas Dalotto-Moreno; Santiago P Méndez-Huergo; Ivan D Mascanfroni; Sebastián Dergan-Dylon; Marta A Toscano; Julio J Caramelo; Juan J García-Vallejo; Jing Ouyang; Enrique A Mesri; Melissa R Junttila; Carlos Bais; Margaret A Shipp; Mariana Salatino; Gabriel A Rabinovich
Journal:  Cell       Date:  2014-02-13       Impact factor: 41.582

Review 6.  Tu-be or not tu-be: that is the question… about serous ovarian carcinogenesis.

Authors:  G Chene; J Dauplat; N Radosevic-Robin; A Cayre; F Penault-Llorca
Journal:  Crit Rev Oncol Hematol       Date:  2013-03-22       Impact factor: 6.312

7.  p53 autoantibodies, cytokine levels and ovarian carcinogenesis.

Authors:  Miyun Tsai-Turton; Antonio Santillan; Dan Lu; Robert E Bristow; Kwun C Chan; Ie-Ming Shih; Richard B S Roden
Journal:  Gynecol Oncol       Date:  2009-04-26       Impact factor: 5.482

8.  Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer.

Authors:  Faruk Tas; Senem Karabulut; Murat Serilmez; Rumeysa Ciftci; Derya Duranyildiz
Journal:  Tumour Biol       Date:  2013-12-04

Review 9.  Chronic inflammation and cytokines in the tumor microenvironment.

Authors:  Glauben Landskron; Marjorie De la Fuente; Peti Thuwajit; Chanitra Thuwajit; Marcela A Hermoso
Journal:  J Immunol Res       Date:  2014-05-13       Impact factor: 4.818

10.  Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer.

Authors:  P Zhang; P Zhang; B Shi; M Zhou; H Jiang; H Zhang; X Pan; H Gao; H Sun; Z Li
Journal:  Cell Death Dis       Date:  2014-01-09       Impact factor: 8.469

View more
  12 in total

Review 1.  Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.

Authors:  Hua Zheng; Masha Zeltsman; Marjorie G Zauderer; Takashi Eguchi; Raj G Vaghjiani; Prasad S Adusumilli
Journal:  Immunotherapy       Date:  2017-09       Impact factor: 4.196

2.  Frequent adaptive immune responses against arginase-1.

Authors:  Evelina Martinenaite; Rasmus Erik Johansson Mortensen; Morten Hansen; Morten Orebo Holmström; Shamaila Munir Ahmad; Nicolai Grønne Dahlager Jørgensen; Özcan Met; Marco Donia; Inge Marie Svane; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2017-12-26       Impact factor: 8.110

3.  IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer.

Authors:  Purushottam Lamichhane; Lavakumar Karyampudi; Barath Shreeder; James Krempski; Deborah Bahr; Joshua Daum; Kimberly R Kalli; Ellen L Goode; Matthew S Block; Martin J Cannon; Keith L Knutson
Journal:  Cancer Res       Date:  2017-10-09       Impact factor: 12.701

Review 4.  Regulatory T Cells in Angiogenesis.

Authors:  Zala Lužnik; Sonia Anchouche; Reza Dana; Jia Yin
Journal:  J Immunol       Date:  2020-11-15       Impact factor: 5.426

5.  Ovarian cancer and the immune system.

Authors:  Thaïs Baert; Ignace Vergote; An Coosemans
Journal:  Gynecol Oncol Rep       Date:  2017-01-06

Review 6.  Surgical trauma-induced immunosuppression in cancer: Recent advances and the potential therapies.

Authors:  Fan Tang; Yan Tie; Chongqi Tu; Xiawei Wei
Journal:  Clin Transl Med       Date:  2020-01

7.  Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma.

Authors:  Mano Nakamura; Heather J Bax; Daniele Scotto; Elmira Amiri Souri; Sam Sollie; Robert J Harris; Niklas Hammar; Goran Walldius; Anna Winship; Sharmistha Ghosh; Ana Montes; James F Spicer; Mieke Van Hemelrijck; Debra H Josephs; Katie E Lacy; Sophia Tsoka; Sophia N Karagiannis
Journal:  Oncoimmunology       Date:  2019-03-28       Impact factor: 8.110

8.  Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma.

Authors:  Malgorzata Czystowska-Kuzmicz; Anna Sosnowska; Dominika Nowis; Kavita Ramji; Marta Szajnik; Justyna Chlebowska-Tuz; Ewa Wolinska; Pawel Gaj; Magdalena Grazul; Zofia Pilch; Abdessamad Zerrouqi; Agnieszka Graczyk-Jarzynka; Karolina Soroczynska; Szczepan Cierniak; Robert Koktysz; Esther Elishaev; Slawomir Gruca; Artur Stefanowicz; Roman Blaszczyk; Bartlomiej Borek; Anna Gzik; Theresa Whiteside; Jakub Golab
Journal:  Nat Commun       Date:  2019-07-05       Impact factor: 14.919

9.  Opposite Macrophage Polarization in Different Subsets of Ovarian Cancer: Observation from a Pilot Study.

Authors:  Ann Vankerckhoven; Roxanne Wouters; Thomas Mathivet; Jolien Ceusters; Thaïs Baert; Anaïs Van Hoylandt; Holger Gerhardt; Ignace Vergote; An Coosemans
Journal:  Cells       Date:  2020-01-27       Impact factor: 6.600

10.  Galectin-1 as a predictive biomarker in ovarian cancer.

Authors:  Mahak Masoodi; Zafar A Shah; Afaq H Beigh; Sheikh Zahoor Ahmad; Abdul Wahid Mir; Besina Yasin; Roohi Rasool; Khalid Z Masoodi; Gull Mohammad Bhat
Journal:  J Ovarian Res       Date:  2021-09-23       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.